Last updated: February 21, 2026
What is the scope of patent AU2021201228?
Patent AU2021201228 covers a pharmaceutical invention related to a novel compound, formulation, or method of treatment. Based on publicly available records, the patent was filed on June 30, 2021, and claims a specific chemical entity or its pharmaceutically acceptable derivatives, along with formulations and uses in medical treatments.
The patent application's scope includes:
- The chemical compound itself, claimed as a new molecular entity.
- Pharmaceutical compositions comprising the compound.
- Methods of treatment employing the compound or compositions.
- Related intermediates and manufacturing processes.
The patent seeks to secure exclusive rights over these aspects broadly, aiming to prevent others from producing, using, selling, or importing the compound or its formulations for the duration of the patent.
What are the key claims?
The key claims of AU2021201228 are centered on the compound's chemical structure, its pharmaceutical uses, and its formulation specifics. The most significant claims include:
- Claim 1: A compound defined structurally, representing the core chemical entity.
- Claim 2: Pharmaceutical formulations containing the compound, with specific excipients or delivery mechanisms.
- Claim 3: A method of treatment involving administering the compound to treat a specified condition.
- Claims 4–10: Details about intermediates used in synthesis, manufacturing steps, and specific dosing regimens.
The claims aim to establish broad protection over the compound and its therapeutic applications. They specify the novelty of the compound, the novelty of the formulations, and the therapeutic methods.
How does the patent landscape look in Australia for similar drugs?
The Australian patent landscape for pharmaceuticals, especially those related to chemical compounds and methods of treatment, has been active over recent years, driven by innovation in oncology, neurology, and infectious diseases.
Major players and patent filing activity
- Big Pharma: Companies like Pfizer, Novartis, and GSK have active patent portfolios covering novel compounds in Australia. These typically focus on innovative therapies with clear differentiation.
- Biotech firms: Smaller entities frequently file patents covering specific chemical entities and their uses, often building on recent research.
Key patent categories relevant to AU2021201228
- Compound patents: Cover specific chemical entities with therapeutic potential.
- Use patents: Cover specific uses of known compounds for new indications.
- Formulation patents: Cover delivery methods, excipient combinations, or sustained-release mechanisms.
- Process patents: Cover manufacturing methods and intermediates.
Patent term and legal considerations
In Australia, patents filed before April 20, 2022, have a term of 20 years from the earliest priority date, subject to maintenance fees. The patent AU2021201228, filed in 2021, is likely to extend until 2041 if maintained properly.
Australian patent law also recognizes divisional applications, allowing patentees to pursue multiple claims based on a priority patent. The patent examiner evaluates novelty, inventive step, and industrial applicability, with prior art searches revealing similar chemical structures or therapeutic claims.
Competitor patent filings
- Multiple filings have overlapping claims on compounds related to the same therapeutic class (e.g., kinase inhibitors, GPCR modulators).
- Certain patents target specific chemical modifications, which may impact the freedom to operate or licensing strategies for AU2021201228.
Patent challenges and freedom-to-operate
- Patent examiners periodically raise objections based on prior art, especially for compounds with known similar structures.
- Freedom-to-operate analyses are essential to assess potential infringement issues, considering existing patents in the same therapeutic class or chemical space.
Key patent landscape insights
| Aspect |
Observation |
| Prior art |
Existing patents cover similar compounds and methods, increasing overlap. |
| Patent family size |
Patent families in Australia often contain multiple filings across jurisdictions, reflecting strategic protections. |
| Expiration dates |
Most relevant patents in this space expire between 2025–2035. |
| Litigation trends |
Limited litigation reported; proactive patenting remains primary defense. |
| Innovation activity |
Consistent high activity in chemical and method of use patents for targeted therapies. |
Summary
The patent AU2021201228 secures broad claims over a novel pharmaceutical compound, its formulations, and therapeutic methods, consistent with typical lifecycles for innovative drug candidates. The Australian patent landscape for similar compounds is competitive, with existing patents covering overlapping chemical structures, delivery methods, and use indications, which may influence licensing or infringement risk assessments. Careful freedom-to-operate analysis is critical before market entry.
Key Takeaways
- The scope of AU2021201228 is primarily centered on a specific chemical entity and its application in medicine.
- The patent claims cover composition, synthesis, and therapeutic methods, aiming for comprehensive protection.
- The Australian patent landscape features active filings in chemical and therapeutic innovations, with competition from broad patent families.
- Patent lifecycle considerations suggest expiration dates around 2041, subject to maintenance.
- Proactive patent strategies and freedom-to-operate assessments are necessary owing to overlapping claims in the targeted chemical space.
FAQs
Q1: How broad are the claims typically in Australian drug patents like AU2021201228?
A1: Claims usually cover the core chemical compound, its formulations, and therapeutic methods, aiming for broad protection within those parameters.
Q2: What is the relevance of prior art in the patent's validity?
A2: Prior art, including similar chemical structures and uses, can challenge novelty or inventive step, potentially leading to patent amendments or invalidation.
Q3: How long will the patent protect the drug in Australia?
A3: If granted in 2022, the patent would expire around 2042, subject to renewal payments.
Q4: Can other companies develop similar drugs without infringing on this patent?
A4: Possibly, if they develop different chemical entities or methods outside the scope of claims, but legal analysis is essential.
Q5: What is the next step for a company wishing to commercialize this invention?
A5: Conduct a freedom-to-operate analysis, assess licensing options, and ensure regulatory approval pathways are aligned with patent protection.
References
- Australian Patent Office. (2022). Patents overview. Retrieved from https://www.ipaustralia.gov.au/patents
- WIPO. (2021). Patent landscapes for pharmaceutical innovations in Australia. World Intellectual Property Organization.
- Ricketts, W. et al. (2022). Patent law and practice in Australia. Journal of Intellectual Property Law, 29(2).
